Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fungal infections during IL-17 pathway monoclonal antibody therapy in psoriasis
NL-OMON46165Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of secukinumab, ixekizumab, brodalumab and ustekinumab in psoriasis (5 cohorts), sponsored by Radboud University Medical Center. Primary endpoints: Incidence and severity of fungal infections, Immune system function and 2 more. Started Oct 2018; status: recruiting.
02
Drugs
secukinumabixekizumabbrodalumabustekinumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NL-OMON46165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46165.